NO329949B1 - Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft - Google Patents

Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft Download PDF

Info

Publication number
NO329949B1
NO329949B1 NO20024735A NO20024735A NO329949B1 NO 329949 B1 NO329949 B1 NO 329949B1 NO 20024735 A NO20024735 A NO 20024735A NO 20024735 A NO20024735 A NO 20024735A NO 329949 B1 NO329949 B1 NO 329949B1
Authority
NO
Norway
Prior art keywords
treatment
fulvestrant
lesions
breast cancer
patients
Prior art date
Application number
NO20024735A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024735L (no
NO20024735D0 (no
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329949(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20024735D0 publication Critical patent/NO20024735D0/no
Publication of NO20024735L publication Critical patent/NO20024735L/no
Publication of NO329949B1 publication Critical patent/NO329949B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20024735A 2000-04-05 2002-10-02 Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft NO329949B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (3)

Publication Number Publication Date
NO20024735D0 NO20024735D0 (no) 2002-10-02
NO20024735L NO20024735L (no) 2002-11-27
NO329949B1 true NO329949B1 (no) 2011-01-31

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024735A NO329949B1 (no) 2000-04-05 2002-10-02 Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft

Country Status (28)

Country Link
US (2) US20030158166A1 (OSRAM)
EP (2) EP1586323A1 (OSRAM)
JP (1) JP2003528919A (OSRAM)
KR (1) KR100757764B1 (OSRAM)
CN (1) CN1431905A (OSRAM)
AT (1) ATE306270T1 (OSRAM)
AU (2) AU2001244372B2 (OSRAM)
BR (1) BR0109789A (OSRAM)
CA (1) CA2403608A1 (OSRAM)
CH (1) CH1272195H1 (OSRAM)
CZ (1) CZ303096B6 (OSRAM)
DE (1) DE60113975T2 (OSRAM)
DK (1) DK1272195T3 (OSRAM)
EE (1) EE05026B1 (OSRAM)
ES (1) ES2248300T3 (OSRAM)
GB (1) GB0008172D0 (OSRAM)
HU (1) HU230064B1 (OSRAM)
IL (2) IL151932A0 (OSRAM)
IS (1) IS2869B (OSRAM)
MX (1) MXPA02009744A (OSRAM)
NO (1) NO329949B1 (OSRAM)
NZ (1) NZ539603A (OSRAM)
PL (1) PL201175B1 (OSRAM)
RU (1) RU2265438C2 (OSRAM)
SK (1) SK287779B6 (OSRAM)
UA (1) UA80388C2 (OSRAM)
WO (1) WO2001074366A1 (OSRAM)
ZA (1) ZA200207538B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SG194735A1 (en) * 2011-05-09 2013-12-30 Univ Virginia Patent Found Compositions and methods for treating cancer
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US20210253626A1 (en) * 2018-05-24 2021-08-19 Kashiv Biosciences, Llc Prodrugs of fulvestrant
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont USE OF THYROMIMETICS TO TREAT CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
BR0109789A (pt) 2003-01-21
PL201175B1 (pl) 2009-03-31
EP1272195B1 (en) 2005-10-12
NO20024735L (no) 2002-11-27
CA2403608A1 (en) 2001-10-11
US20110183949A1 (en) 2011-07-28
HUP0300339A3 (en) 2009-01-28
ATE306270T1 (de) 2005-10-15
DE60113975D1 (de) 2006-02-23
DK1272195T3 (da) 2006-01-16
GB0008172D0 (en) 2000-05-24
EE05026B1 (et) 2008-06-16
CN1431905A (zh) 2003-07-23
JP2003528919A (ja) 2003-09-30
HU230064B1 (hu) 2015-06-29
CZ303096B6 (cs) 2012-04-04
EP1272195A1 (en) 2003-01-08
IS6576A (is) 2002-10-01
IS2869B (is) 2014-03-15
NO20024735D0 (no) 2002-10-02
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
ZA200207538B (en) 2003-12-19
IL151932A (en) 2007-07-04
WO2001074366A1 (en) 2001-10-11
PL357936A1 (en) 2004-08-09
MXPA02009744A (es) 2004-02-26
US20030158166A1 (en) 2003-08-21
KR20030007501A (ko) 2003-01-23
UA80388C2 (en) 2007-09-25
NZ539603A (en) 2008-02-29
CH1272195H1 (OSRAM) 2019-10-15
SK14292002A3 (sk) 2003-08-05
AU4437201A (en) 2001-10-15
AU2001244372B2 (en) 2006-02-16
DE60113975T2 (de) 2006-06-22
EE200200574A (et) 2004-04-15
HK1051498A1 (en) 2003-08-08
SK287779B6 (sk) 2011-09-05
IL151932A0 (en) 2003-04-10
KR100757764B1 (ko) 2007-09-12
CZ20023309A3 (cs) 2003-02-12
HUP0300339A2 (hu) 2003-06-28
EP1586323A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
US10034860B2 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
Beslija et al. Second consensus on medical treatment of metastatic breast cancer
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
Rugo The breast cancer continuum in hormone-receptor–positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
JP2023504436A (ja) 乳がんの治療のための併用療法
HRP20120084A2 (hr) FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE
Roeca et al. The postmenopausal women
Johnston et al. A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
Ellmén Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer
Woitacki et al. 211 POSTER
i Alsina et al. Selective Estrogen Receptor Modulators. Antonio Cano
Santoro THE POSTMENOPAUSAL WOMAN

Legal Events

Date Code Title Description
MK1K Patent expired